es > en

> ASCO 2016: Genomic Health reinforces its leadership


Genomic Health announced multiple data presentations with Oncotype DX® Breast Recurrence Score™ at the recent 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

The presentations about the test included new results from the European PlanB outcomes study and four new analyses of the Surveillance, Epidemiology, and End Results (SEER) Registry of the U.S. National Cancer Institute (NCI) with more than 44,600 breast cancer patients.

Collectively, these data confirm the test’s ability to accurately predict clinical outcomes, reinforcing the unique value of Oncotype DX as the only multi-gene breast cancer test with prospective outcomes evidence in more than 50,000 patients.

Other news

> Share in